Amgen to acquire Five Prime Therapeutics for $1.9B
- BySeeking Alpha-
Amgen Inc. announced Thursday an agreement to buy biotechnology company Five Prime Therapeutics Inc. in a cash deal valued at $1.9 billion. Five Prime shares were halted for news...
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
The COVID-19 pandemic has created several equity market winners, including pharma giant AstraZeneca (LON:AZN) (NYSE:AZN). The company, along with its partner Oxford University, is...
The stock market finished August with its fifth monthly gain as one of the strongest rallies since 2000 continued pushing higher.Indeed, this rally looks like it has enough...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.